bioAffinity Technologies Faces Delisting Notice
Ticker: BIAFW · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1712762
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: BIAF
TL;DR
BIAF got a notice about possibly getting delisted. Big trouble.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on February 7, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in Delaware and its principal executive offices are located in San Antonio, Texas.
Why It Matters
This filing indicates potential issues with the company's continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- February 7, 2025 (date) — Date of earliest event reported
- San Antonio, Texas (location) — Principal executive offices location
- Delaware (location) — State of incorporation
FAQ
What specific listing rule or standard has bioAffinity Technologies, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice has been received regarding potential delisting or failure to satisfy a continued listing rule.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 7, 2025.
Where are bioAffinity Technologies, Inc.'s principal executive offices located?
The principal executive offices of bioAffinity Technologies, Inc. are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
In which state was bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. was incorporated in Delaware.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number for bioAffinity Technologies, Inc. is 001-41463.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2025-02-07 17:20:41
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $1.00 — maintain a minimum closing bid price of $1.00 ("Minimum Bid Price Requirement") per s
- $1.00 m — ing bid price to equal or to exceed the $1.00 minimum bid price requirement for more th
Filing Documents
- form8-k.htm (8-K) — 38KB
- 0001493152-25-005450.txt ( ) — 252KB
- biaf-20250207.xsd (EX-101.SCH) — 4KB
- biaf-20250207_def.xml (EX-101.DEF) — 26KB
- biaf-20250207_lab.xml (EX-101.LAB) — 36KB
- biaf-20250207_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. bioAffinity Technologies, Inc. By: /s/ Michael Edwards Michael Edwards Chief Financial Officer Dated: February 7, 2025